Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC)

Investigational New Drugs

Volumn 29, Issue 3, 2011, Pages 499-505

  Tran, Hai T ^a   Zinner, Ralph G ^a   Blumenschein Jr , George R ^a   Oh, Yun W ^b   Papadimitrakopoulou, Vassiliki A ^a   Kim, Edward S ^a   Lu, Charles ^a   Malik, Mubashira ^c   Lum, Bert L ^c   Herbst, Roy S ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c GENENTECH INC   (United States)

Author keywords

EGFR inhibitor; Erlotinib; Lung cancer; NSCLC; Pharmacokinetics

Indexed keywords

CARBOPLATIN; DRUG METABOLITE; ERLOTINIB; OSI 420; PACLITAXEL; PLACEBO; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BLOOD SAMPLING; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; COUGHING; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DYSPNEA; FATIGUE; FEMALE; HUMAN; INSOMNIA; LIQUID CHROMATOGRAPHY; LUNG NON SMALL CELL CANCER; MALE; MASS SPECTROMETRY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; PLACEBOS; QUINAZOLINES; TIME FACTORS;

EID: 78650434919     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-009-9380-z     Document Type: Article

References (16)

1. Pollack VA, Savage DM, Baker DA, Tsaparikos KE, Sloan DE, Moyer JD, Barbacci EG, Pustilnik LR, Smolarek TA, Davis JA, Vaidya MP, Arnold LD, Doty JL, Iwata KK, Morin MJ (1999) Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358, 774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice. J Pharmacol Exp Ther 291:739-748 (Pubitemid 29503548)
2. Data on file with OSI Pharmaceuticals
3. Higgins B, Kolinsky K, Smith M, Beck G, Rashed M, Adames V, Linn M, Wheeldon E, Gand L, Birnboeck H, Hoffmann G (2004) Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models. Anticancer Drugs 15:503-512 (Pubitemid 38736950)
4. Hidalgo M, Siu LL, Nemunaitis J, Rizzo J, Hammond LA, Takimoto C, Eckhardt SG, Tolcher A, Britten CD, Denis L, Ferrante K, Von Hoff DD, Silberman S, Rowinsky EK (2001) Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 19:3267-3279 (Pubitemid 32591445)
5. Soulieres D, Senzer NN, Vokes EE, Hidalgo M, Agarwala SS, Siu LL (2004) Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 22:77-85 (Pubitemid 41095117)
6. Patnaik A, Wood D, Tolcher AW, Hamilton M, Kreisberg JI, Hammond LA, Schwartz G, Beeram M, Hidalgo M, Mita MM, Wolf J, Nadler P, Rowinsky EK (2006) Phase I, pharmacokinetic, and biological study of erlotinib in combination with paclitaxel and carboplatin in patients with advanced solid tumors. Clin Cancer Res 12:7406-7413 (Pubitemid 46095415)
7. Ratain MJ, George CM, Janisch L, Kindler HL, Ryan C, Wood DL, Nadler PI, Vokes EE (2002) Phase I trial of erlotinib (OSI-774) in combination with gemcitabine (G) and cisplatin (P) in patients with advanced solid tumors. Proc Am Soc Clin Oncol 21:76 (Abstract 2115)
8. Herbst RS, Prager D, Hermann R, Fehrenbacher L, Johnson BE, Sandler A, Kris MG, Tran HT, Klein P, Li X, Ramies D, Johnson DH (2005) TRIBUTE Investigator Group. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 23:5892-5899
9. Ling J, Johnson K, Miao Z, Rakhit A, Pantze M, Hamilton M, Lum B, Prakash C (2006) Metabolism and excretion of erlotinib, a small molecule inhibitor of epidermal growth factor receptor tyrosine kinase, in healthy male volunteers. Drug Metab Dispos 34:420-426 (Pubitemid 43290900)
10. Canal PR (1998) Cisplatin, carboplatin, and platinum analogs. In: Growchow LB, Ames MM (eds) A clinicians guide to chemotherapy pharmacokinetics and pharmacodynamics. Williams and Wilkins, Baltimore, pp 345-374
11. Relling M, Sonnichen D (1998) Paclitaxel and Docetaxel. In: Growchow LB, Ames MM (eds) A clinicians guide to chemotherapy pharmacokinetics and pharmacodynamics. Williams and Wilkins, Baltimore, pp 3375-3394
12. Declaration of Helsinki. Adopted by the 18th World Medical Assembly, Helsinki, Finland, June 1964, amended by the 29th World Medical Assembly, Tokyo, Japan, October 1975, and the 35th World Medical Assembly, Venice, Italy, October, 1983
13. Foursorouzesh B, Hidalgo M, Takimoto C, de Bono JS, Forero L, Muralidhar B, Malik S, Patnaik A, Rizzo J, Hammond LA, Schwartz G, Goetz A, Mays T, Kiene A, Norris J, Tolcher A, Rowinsky EK, Nadler P, Wood D, Zitelli A (2002) Phase I, pharmacokinetic (PK), and biological studies of the epidermal growth factor-tyrosine kinase (EGFR-TK) inhibitor OSI-774 in combination with docetaxel. Proc Am Soc Clin Oncol 21:21 (Abstract 81)
14. Shepherd FA, Pereira JR, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabárbara P, Seymour L (2005) National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123-132 (Pubitemid 41058344)
15. MooreMJ, GoldsteinD, HammJ, FigerA, Hecht JR, Gallinger S,Au HJ,Murawa P,WaldeD,Wolff RA, CamposD, LimR,DingK, Clark G,Voskoglou-Nomikos T, PtasynskiM, ParulekarW(2007) National Cancer Institute of Canada Clinical Trials Group. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960-1966 (Pubitemid 46972777)
16. Gatzemeier U, Pluzanska A, Szczesna A, Kaukel E, Roubec J, De Rosa F, Milanowski J, Karnicka-Mlodkowski H, Pesek M, Serwatowski P, Ramlau R, Janaskova T, Vansteenkiste J, Strausz J, Manikhas GM, Von Pawel J (2007) Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol 25(12):1545-1552 (Pubitemid 46733081)